论文部分内容阅读
目的:探讨恩度抑制异位内膜生长的作用及机制,为恩度用于临床治疗子宫内膜异位症提供理论依据。方法:采用腹腔种植的方法建立子宫内膜异位症裸鼠模型。造模3周后,随机分为恩度组与对照组,每组15只。用恩度腹腔给药治疗,疗程结束后观察异位内膜的变化情况,并取血清、腹腔液分别检测VEGF、TNF-α的水平。结果:恩度组的细胞因子水平明显低于对照组(P<0.05),内膜腺体见萎缩。结论:恩度可以明显抑制VEGF水平,进而抑制异位内膜的血管生长,达到治疗EMS的目的。
OBJECTIVE: To investigate the effect and mechanism of Endue on the inhibition of ectopic endometrial growth, and to provide a theoretical basis for Endostar for clinical treatment of endometriosis. Methods: The nude mouse models of endometriosis were established by intraperitoneal implantation. After 3 weeks of modeling, they were randomly divided into Endurance group and control group, 15 rats in each group. Endometriosis was used to treat the endometriosis. Endometriosis changes were observed after the end of treatment. Serum and peritoneal fluid were collected to detect the levels of VEGF and TNF-α. Results: Endostar group cytokines levels were significantly lower than the control group (P <0.05), endometrial glands atrophy. Conclusion: Endostar can significantly inhibit the level of VEGF, and then inhibit the growth of ectopic endometrium to achieve the purpose of the treatment of EMS.